Vagus nerve stimulation (VNS™) for treatment-resistant depression: Efficacy, side effects, and predictors of outcome

Neuropsychopharmacology

Volumn 25, Issue 5, 2001, Pages 713-728

  Sackeim, Harold A ^a,b   Rush, A John ^c   George, Mark S ^d,e   Marangell, Lauren B ^f   Husain, Mustafa M ^c   Nahas, Ziad ^d   Johnson, Christopher R ^f   Seidman, Stuart ^a,b   Giller, Cole ^c   Haines, Stephen ^d   Simpson Jr , Richard K ^f   Goodman, Robert R ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b The New York Presbyterian Hospital   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^e RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Clinical trial; Efficacy; Major depressive disorder; Side effects; Treatment resistant depression; Vagus nerve stimulation

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; LORAZEPAM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DEVICE; FEMALE; HOARSENESS; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MANIC DEPRESSIVE PSYCHOSIS; MULTICENTER STUDY; OUTCOMES RESEARCH; PILOT STUDY; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; DEPRESSIVE DISORDER; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; ELECTROCONVULSIVE THERAPY; ELECTRODES, IMPLANTED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; TREATMENT OUTCOME; VAGUS NERVE;

EID: 0034784012     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00271-8     Document Type: Article

References (42)

1. Vagus nerve stimulation for treatment of seizures?
2. Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures
3. Vagus nerve stimulation for treatment of partial seizures. 1. A controlled study of effect on seizures
4. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression
5. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures
6. Vagus nerve stimulation is associated with mood improvements in epilepsy patients
7. Vagus nerve stimulation. A potential therapy for resistant depression?
8. Vagus nerve stimulation: A new tool for brain research and therapy
9. Vagus nerve stimulation for treatment of partial seizures. 3. Long-term follow-up on first 67 patients exiting a controlled study
10. Development of a rating scale for primary depressive illness
11. Vagus nerve stimulation therapy for partial-onset seizures: A randomized active-control trial
12. Effect of vagus nerve stimulation on mood in adult epilepsy patients
13. Brain blood flow alterations induced by therapeutic vagus nerve stimulation in partial epilepsy. I. Acute effects at high and low levels of stimulation
14. Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation
15. Antidepressant specificity in atypical depression
16. A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression
17. A new depression scale designed to be sensitive to change
18. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy
19. Antidepressant treatment is inadequate in patients with major depression who are at risk for suicidal behavior
20. A history of the use of anticonvulsants as mood stabilizers in the last two decades of the 20th century
21. Resistance to antidepressant medications and short-term clinical response to ECT
22. Medication resistance and clinical response to electroconvulsive therapy
23. Phenelzine versus imipramine in the treatment of probable atypical depression: Defining syndrome boundaries of selective MAOI responders
24. Further evidence that a placebo response to antidepressants can be identified
25. Placebo run-in period in studies of depressive disorders. Clinical, heuristic and research implications
26. Vagus nerve stimulation (VNS™) for treatment-resistant depressions: A multicenter study
27. The anticonvulsant hypothesis of the mechanisms of action of ECT: Current status
28. Anticonvulsant and antidepressant properties of electroconvulsive therapy: A proposed mechanism of action
29. The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression
30. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression
31. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities
32. Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial
33. Vagus nerve stimulation
34. Prophylactic efficacy of phenelzine and imipramine in chronic atypical depression: Likelihood of recurrence on discontinuation after 6 months' remission
35. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures
36. Long-term results of vagus nerve stimulation in refractory epilepsy
37. Regulation of limbic motor seizures by GABA and glutamate transmission in nucleus tractus solitarius
38. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection
39. A rating scale for mania: Reliability, validity and sensitivity